MedTrace Logo

Corticosteroid Use in Premature Babies and Lung Ultrasonografi Use in the Progression to Bronchopulmonary Dysplasia

NCT05621785 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-11-18

No results posted yet for this study

Summary

Bronchopulmonary dysplasia (BPD) is one of the most common morbidities in premature infants and is associated with poor neurodevelopmental outcomes . Although mechanical ventilation and oxygen requirements in premature infants have been identified as triggering mechanisms for the development of inflammation and BPD over time, data now support that a number of perinatal events that may stimulate the inflammatory cascade before birth also have important effects. Corticosteroids such as dexamethasone and hydrocortisone have proven to be beneficial for the prevention and management of postpartum BPD due to their anti-inflammatory properties . With this study, the effects of corticosteroid use on lung ultrasound findings in BPD will be investigated, and acute and chronic lung ultrasonography scores will be recorded. A prospective observational study was planned in the neonatal intensive care unit between 2022 and 2024 in premature infants below 32 weeks of gestational age. Demographic data and Lung Ultrasonography findings of these babies will be recorded. Among the patients who are predicted to go to BPD, in the group using corticosteroids, Lung Ultrasonographic imaging will be performed and the effect of corticosteroids on pulmonary findings will be recorded. It is planned to investigate whether postnatal steroid use has an effect on lung ultrasound findings in preterm infants with BPD.

Conditions

  • Bronchopulmonary Dysplasia
  • Premature Birth

Interventions

DEVICE

Lung Ultrasonografi

All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG

Sponsors & Collaborators

  • Kırıkkale University

    lead OTHER

Principal Investigators

  • Sevde Nur Vural, Asistant Dr · KIRIKKALE UNİVERSİTY FACULTY OF MEDİCİNE

Eligibility

Min Age
1 Day
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-03-30
Completion
2024-03-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05621785 on ClinicalTrials.gov